Simcere Pharmaceutical Statements
20
Simcere Pharmaceutical Income Statement
B
M
CNY (except Earnings per share)
Financial
Revenue
Cost of sales
Gross profit
Research and development
Selling, general and administrative
Total operating expenses
Operating income
Interest expense
Other income
Income before tax
Provision for income taxes
Net income
Diluted earnings per share
Shares outstanding after dilution
3 228.48
100
805.62
25
2 422.85
75
787.25
24.4
1 351.8
41.9
2 064
63.9
358.85
11.1
-1 912.99
-59.3
—
0
-1 585.14
-49.1
-25.258
-0.8
-1 559.89
-48.3
-0.6
2 598.12
3 379.33
100
818.03
24.2
2 561.3
75.8
775.89
23
1 503
44.5
2 202.44
65.2
358.86
10.6
1 176.25
34.8
—
0
2 325.18
68.8
51.346
1.5
2 274.65
67.3
0.869
2 618.95
3 624.43
100
770.03
21.2
2 854.4
78.8
1 076.75
29.7
1 637.09
45.2
2 419.21
66.7
435.19
12
409.11
11.3
—
0
833.73
23
-31.08
-0.9
867.08
23.9
0.331
2 622.38
2 699.65
100
557.37
20.6
2 142.28
79.4
651.54
24.1
1 197.78
44.4
1 762.19
65.3
380.09
14.1
-327.56
-12.1
—
0
52.523
1.9
-9.398
-0.3
63.784
2.4
0.024
2 618.37
2 879.72
100
623.01
21.6
2 256.71
78.4
789.92
27.4
1 385.9
48.1
2 088.98
72.5
167.73
5.8
709.75
24.6
—
0
879.96
30.6
-64.069
-2.2
949.28
33
0.363
2 614.07
2 120
100
456.98
21.6
1 663.03
78.4
626.8
29.6
1 033.29
48.7
1 597.42
75.4
65.602
3.1
-46.641
-2.2
—
0
521.84
24.6
-33.055
-1.6
557.81
26.3
0.214
2 608.64
2 583.31
100
511.8
19.8
2 071.51
80.2
687.9
26.6
1 159.88
44.9
1 876.6
72.6
194.91
7.5
376.79
14.6
—
0
580.36
22.5
100.9
3.9
484.02
18.7
0.198
2 440.16
1 925.41
100
388.13
20.2
1 537.28
79.8
454.09
23.6
821.97
42.7
1 232.98
64
304.3
15.8
-79.826
-4.1
—
0
224.73
11.7
39.898
2.1
185.52
9.6
0.079
2 345.12